Wang Y - Search Results

1

Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.

Xue T, Ding S, Guo B, Zhou Y, Sun P, Wang H, Chu W, Gong G, Wang Y, Chen X, Yang Y. Xue T, et al. Among authors: wang h, wang y. J Med Chem. 2014 Sep 25;57(18):7770-91. doi: 10.1021/jm501045e. Epub 2014 Sep 15. J Med Chem. 2014. PMID: 25179681

2

Engineering Factor Xa Inhibitor with Multiple Platelet-Binding Sites Facilitates its Platelet Targeting.

Zhu Y, Li R, Lin Y, Shui M, Liu X, Chen H, Wang Y. Zhu Y, et al. Among authors: wang y. Sci Rep. 2016 Jul 19;6:29895. doi: 10.1038/srep29895. Sci Rep. 2016. PMID: 27432161 Free PMC article.

3

Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition.

Zhu Y, Lin Y, Liu X, Hu W, Wang Y. Zhu Y, et al. Among authors: wang y. Biochem Biophys Res Commun. 2017 Jan 29;483(1):495-501. doi: 10.1016/j.bbrc.2016.12.116. Epub 2016 Dec 19. Biochem Biophys Res Commun. 2017. PMID: 28007598

4

Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.

Wang J, Tan H, Sun Q, Ge Z, Wang X, Wang Y, Li R. Wang J, et al. Among authors: wang x, wang y. Bioorg Med Chem Lett. 2015 Jun 1;25(11):2340-4. doi: 10.1016/j.bmcl.2015.04.013. Epub 2015 Apr 10. Bioorg Med Chem Lett. 2015. PMID: 25899312

5

Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors.

Zhu Y, Lin Y, Liu A, Shui M, Li R, Liu X, Hu W, Wang Y. Zhu Y, et al. Among authors: wang y. Biochem Pharmacol. 2015 Jun 15;95(4):253-62. doi: 10.1016/j.bcp.2015.04.004. Epub 2015 Apr 15. Biochem Pharmacol. 2015. PMID: 25887920

6

Design and evaluation of EphrinA1 mutants with cerebral protective effect.

Zhu Y, Gao Y, Zheng D, Shui M, Yu K, Liu X, Lin Y, Su L, Yang W, Wang Y. Zhu Y, et al. Among authors: wang y. Sci Rep. 2017 May 15;7(1):1881. doi: 10.1038/s41598-017-02091-7. Sci Rep. 2017. PMID: 28507312 Free PMC article.

7

Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug.

Han HH, Zhang HT, Wang R, Yan Y, Liu X, Wang Y, Zhu Y, Wang JC. Han HH, et al. Among authors: wang y, wang r, wang jc. Int J Pharm. 2020 Nov 15;589:119869. doi: 10.1016/j.ijpharm.2020.119869. Epub 2020 Sep 10. Int J Pharm. 2020. PMID: 32919000

8

Engineering novel anticoagulant proteins by motif grafting.

Zhu Y, Liu A, Liu X, Wang Y. Zhu Y, et al. Among authors: wang y. Protein Pept Lett. 2014;21(2):159-63. doi: 10.2174/092986652102131226112049. Protein Pept Lett. 2014. PMID: 24370339

9

Engineering a "three-in-one" hirudin prodrug to reduce bleeding risk: A proof-of-concept study.

Zhu Y, Han HH, Zhai L, Yan Y, Liu X, Wang Y, Lei L, Wang JC. Zhu Y, et al. Among authors: wang y, wang jc. J Control Release. 2021 Oct 10;338:462-471. doi: 10.1016/j.jconrel.2021.08.058. Epub 2021 Sep 1. J Control Release. 2021. PMID: 34481024

10

Improvement and Application of Acute Blood Stasis Rat Model Aligned with the 3Rs (Reduction, Refinement and Replacement) of Humane Animal Experimentation.

Huang S, Xu F, Wang YY, Shang MY, Wang CQ, Wang X, Cai SQ. Huang S, et al. Chin J Integr Med. 2020 Apr;26(4):292-298. doi: 10.1007/s11655-014-2008-y. Epub 2014 Dec 23. Chin J Integr Med. 2020. PMID: 25537151

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299,323 results

Search Page

Filters